Drug Trial Radar · NCT01201356
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Apr 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,125
Actual
Start
Sep 13, 2010
Primary completion
Oct 19, 2018
Study completion Oct 19, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study combined all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that provided patients with continuous treatment until fingolimod was registered, commercially available, and reimbursed in the respective countries.
Conditions
- Relapsing Forms of Multiple Sclerosis
Interventions
FingolimodDrug
0.5 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and DeathTime frame: Baseline (Part I) to Month 6 Follow-up (Part II), up to 8 years
Locations
458 sites in 38 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Cullman, Alabama
Novartis Investigative Site
Oceanside, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Washington D.C., District of Columbia
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Maitland, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Sunrise, Florida
Novartis Investigative Site
Tallahassee, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Vero Beach, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Kansas City, Kansas
Novartis Investigative Site
Lenexa, Kansas
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Kansas City, Missouri
Novartis Investigative Site
Lebanon, New Hampshire
Novartis Investigative Site
Albuquerque, New Mexico
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Durham, North Carolina
Novartis Investigative Site
Raleigh, North Carolina
Novartis Investigative Site
Toledo, Ohio
Novartis Investigative Site
Oklahoma City, Oklahoma
Novartis Investigative Site
Tulsa, Oklahoma
Novartis Investigative Site
Tualatin, Oregon
Novartis Investigative Site
Pittsburgh, Pennsylvania
Novartis Investigative Site
Bristol, Tennessee
Novartis Investigative Site
Nashville, Tennessee
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Burlington, Vermont
Novartis Investigative Site
Charlottesville, Virginia
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Salta, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina
Showing 40 of 458 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.